Table 1 Clinical characteristics of CH-ITP patients (VAF ≥ 2%) and patients with low-burden mutations (1% < VAF < 2%).
From: Clonal hematopoiesis in primary immune thrombocytopenia
Patient ID | Age | Sex | Smoking history | Platelet count (×109/L) | Disease duration (months) | Gene | VAF | Malignant transformation | Previous/present treatments | Initial response to corticosteroid | Refractory ITP | Bleeding symptoms | Bleeding score |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ITP1 | 71 | M | Yes | 7 | 6 | DNMT3A | 0.0466 | No | Dex, Pred, Rit, TPO-RA | NR | Yes | EP EC | S1M1 |
ITP2 | 72 | F | No | 11 | 1.5 | ASXL1 | 0.0539 | No | Dex, rhTPO,Rit, TPO-RA | NR | Yes | EC GH | S1M1 |
ITP3 | 31 | F | No | 1 | 72 | DNMT3A | 0.0454 | No | Dex. IVIg, Rit, TPO-RA, Tacrolimus | NR | Yes | EC GI GYN ICH | S1O2 (intracranial3) |
ITP4 | 62 | F | No | 13 | 8 | DNMT3A | 0.0692 | No | Dex | R | No | PT | S1 |
ITP5 | 45 | F | No | 7 | 1 | TP53 | 0.0739 | No | Dex, Chinese medicine | CR | No | EC | S1 |
ITP6 | 84 | M | No | 19 | 24 | SRSF2 | 0.0588 | No | Pred, Dex | R | No | EC | S1 |
ITP7 | 84 | M | Yes | 26 | 0.5 | ASXL1 | 0.0945 | No | Pred, rhTPO | NR | No | No | 0 |
ITP8 | 50 | M | Yes | 5 | 48 | DNMT3A | 0.0290 | No | IVIg | - | No | EC GI | S1O2 |
ITP9 | 69 | M | Yes | 4 | 2.5 | TET2 | 0.0625 | No | Pred, TPO-RA | R | No | GH | M1 |
ITP10 | 56 | F | No | 14 | 12 | DNMT3A | 0.0313 | No | Dex, IVIG, rhTPO, Rit | NR | Yes | GH EP | M2 |
ITP11 | 67 | F | No | 1 | 0.1 | DNMT3A TET2 | 0.0540 0.0580 | No | Pred | CR | No | GH EP GUH | M3 |
ITP12 | 54 | M | No | 6 | 348 | CEBPA | 0.0125 | No | Pred, rhTPO, Spl | NR | Yes | EC GH | S1M1 |
ITP13 | 67 | M | No | 8 | 132 | DNMT3A | 0.0171 | No | Dex, Pred | CR | No | No | 0 |
ITP14 | 50 | M | Yes | 3 | 180 | SF3B1 | 0.0129 | No | Pred, CsA, IL-11, rhTPO, TPO-RA, Rit | R | Yes | GUH GH EP | M2O2 |
